Evaluating the managed care implications of longer-acting basal insulin analog therapies.
This article spotlights the outcomes of the phase 3 clinical trials for these newer formulations, as well as more recent meta-analyses and real-world studies. It also highlights the implications for managed care plans as they move to add these insulins to their formularies.
PMID: 29620817 [PubMed - in process]
Source: The American Journal of Managed Care - Category: Health Management Authors: Logan T, Daisy B Tags: Am J Manag Care Source Type: research
More News: Clinical Trials | Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Epidemics | Epidemiology | Health Management | Insulin | Lantus | Managed Care | Study | USA Health | Victoza